I read with interest the article by Høeg et al. ([@B1]) in the January issue of *Diabetes* in which the authors concluded that there is a sex difference in the response in free fatty acid (FFA)-induced skeletal muscle insulin resistance following a lipid infusion in nonobese healthy humans. This was based on a rather small difference of marginal statistical significance (*P* \< 0.05), and it was only the case for the glucose infusion over 120 min (Fig. 1*B*), but not over the last 30 min (which would be of greater value because it is closer to steady state; Fig. 1*A*) or when expressed by overall kilogram of body mass (31 ± 3 vs. 29 ± 4 μmol/min/kg) or as the delta leg glucose uptake (Fig. 1*F*). It is also unclear whether the authors used the glucose infusion rate (as stated in the figures) or meant insulin-stimulated glucose uptake (*R~d~*) from the ^3^H-glucose reported, which would have been more precise but unlikely in steady state only 5 h after breakfast. I would have indeed expected a greater sex difference from the ∼20% higher plasma FFA concentration in men prior to the insulin clamp experiments (statistically not significant per the authors), which was clinically relevant as suggested by their 45% higher plasma triglyceride levels (men: 2,478 vs. women: 1,706 mg/dL, *P* \< 0.05). Both the higher plasma FFA and triglycerides persisted until the end of the clamp study.

My colleagues and I have previously reported no sex difference in lipid-induced skeletal muscle insulin resistance after an acute lipid infusion of similar duration than reported in the article by Høeg et al. ([@B1]), with plasma FFA ranging in dose-response studies from the physiological (plasma FFA ∼700 μmol//L) to the pharmacological (∼2,000 μmol/L as in the current study) range ([@B2]). Of note, the authors overlooked this work when they stated in the introduction that only one prior study included women (ref. 8 of the article), although they do quote our study in the [discussion]{.smallcaps} section when acknowledging the reported inhibition of insulin signaling by lipid infusion. Intrigued by the work of Høeg et al., my colleagues and I reanalyzed our prior studies to again observe no sex difference to chronic lipid-induced insulin resistance in healthy control subjects after 48 ([@B3]) or 96 ([@B4]) hours of lipid infusion that raised the plasma FFA concentration by ∼twofold (this effect on sex has not been reported before by us).

It is unclear in the article by Høeg et al. ([@B1]) the mechanism(s) for the induction of insulin resistance by lipid infusion, since neither insulin signaling was impaired nor was there an accumulation of toxic lipid-derived metabolites (i.e., diacylglycerols, ceramides, other) or induction of inflammatory pathways. This is in contrast to a large body of data in vitro, in vivo, and in humans ([@B2],[@B4], and reviewed in [@B5],[@B6]) suggesting that these mechanisms interact and are likely to play a role in lipid-induced skeletal muscle insulin resistance. While we all know that "current dogma" is not equivalent to the truth, the lack of a strong alternative hypothesis for the observed lipid-induced insulin resistance by Høeg et al. ([@B1]) should be a call for caution about the conclusions and stimulate future studies.
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